AxoGen (NASDAQ: AXGN) and Integer (NYSE:ITGR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.
Institutional and Insider Ownership
66.0% of AxoGen shares are owned by institutional investors. Comparatively, 95.0% of Integer shares are owned by institutional investors. 9.3% of AxoGen shares are owned by insiders. Comparatively, 4.8% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares AxoGen and Integer’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares AxoGen and Integer’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AxoGen||$41.11 million||23.22||-$14.41 million||($0.42)||-66.67|
|Integer||$1.39 billion||1.11||$5.96 million||$0.64||75.86|
Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
AxoGen has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.
This is a breakdown of current recommendations for AxoGen and Integer, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AxoGen presently has a consensus target price of $29.33, indicating a potential upside of 4.76%. Integer has a consensus target price of $51.00, indicating a potential upside of 5.05%. Given Integer’s higher possible upside, analysts clearly believe Integer is more favorable than AxoGen.
Integer beats AxoGen on 10 of the 14 factors compared between the two stocks.
AxoGen Company Profile
AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Integer Company Profile
Greatbatch, Inc. is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical’s products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets. QiG focuses on developing medical device systems for some of healthcare’s challenges and reflects the Company’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with OEM customers and strategic equity positions in emerging healthcare companies.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.